Acumen Pharmaceuticals (ABOS) Preferred Stock Liabilities (2020 - 2021)
Acumen Pharmaceuticals (ABOS) reported Preferred Stock Liabilities of $174.5 million for Q2 2021, up 208.02% sequentially from $56.7 million in Q4 2020.
Acumen Pharmaceuticals (ABOS) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Acumen Pharmaceuticals (ABOS) has 2 years of Preferred Stock Liabilities data on file, last reported at $174.5 million in Q2 2021.
- For the quarter ending Q2 2021, Preferred Stock Liabilities changed N/A year-over-year to $174.5 million; the trailing twelve-month figure through Jun 2021 stood at $174.5 million (changed N/A YoY), and the FY2020 full-year result was $56.7 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $174.5 million in Q2 2021, from $56.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $174.5 million in Q2 2021 to a low of $56.7 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Acumen Pharmaceuticals | 140.98 Mn | 140.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 174.50 Mn |
| Dec 31, 2020 | 56.65 Mn |